Hormonal
AMG 133 (maridebart cafraglutide), a bispecific molecule combining a GIP receptor antagonist with a GLP-1 receptor agonist, produces pronounced, dose-dependent weight loss and improves metabolic parameters in adults with obesity.
AMG 133 is a new injectable medication for obesity that works by targeting two gut hormones (GLP-1 and GIP). In early clinical trials, it caused significant weight loss (up to 14.5% of body weight) with a dosing schedule of just one injection every four weeks. While it can cause temporary nausea or vomiting, these side effects are usually mild and go away quickly. It is currently in clinical trials and not yet widely available.
In a phase 1, randomized, double-blind, placebo-controlled clinical study in participants with obesity (NCT04478708), AMG 133 had an acceptable safety and tolerability profile along with pronounced dose-dependent weight loss.
Why this rating
Phase 1 clinical trial data (n=49) is robust for safety and proof-of-concept efficacy but lacks long-term outcomes and large-scale statistical power.
Source
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Murielle M. Véniant et al. · Nature Metabolism · 2024
DOI 10.1038/s42255-023-00966-w
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →